EXACT Sciences Corporation (EXAS) Analysts See $-0.37 EPS

July 17, 2017 - By Kurt Siggers

 EXACT Sciences Corporation (EXAS) Analysts See $ 0.37 EPS
Investors sentiment decreased to 1.08 in 2016 Q4. Its down 0.40, from 1.48 in 2016Q3. It worsened, as 35 investors sold EXACT Sciences Corporation shares while 56 reduced holdings. 31 funds opened positions while 67 raised stakes. 88.31 million shares or 1.12% more from 87.34 million shares in 2016Q3 were reported.
Fincl Advisory Ser Inc accumulated 0.04% or 10,000 shares. Rock Springs Management L P invested 0.4% in EXACT Sciences Corporation (NASDAQ:EXAS). State Bank Of America De stated it has 235,465 shares. Campbell Company Inv Adviser Limited Liability Company reported 0.54% of its portfolio in EXACT Sciences Corporation (NASDAQ:EXAS). Primecap Management Ca has 4.49M shares. California Pub Employees Retirement Systems invested in 182,400 shares or 0% of the stock. M&T Bancorporation invested in 19,628 shares or 0% of the stock. 251,946 were accumulated by Antipodean Advsrs Lc. Pacad, British Columbia – Canada-based fund reported 25,100 shares. Ubs Asset Americas reported 1.88M shares. Nationwide Fund owns 98,082 shares or 0.01% of their US portfolio. Blackrock stated it has 76,434 shares or 0% of all its holdings. Arrowpoint Asset Mgmt Llc invested 0.65% of its portfolio in EXACT Sciences Corporation (NASDAQ:EXAS). Raymond James Advisors has invested 0% in EXACT Sciences Corporation (NASDAQ:EXAS). Proshare Advsr Limited Liability Com stated it has 16,981 shares.

Since February 24, 2017, it had 0 insider purchases, and 9 selling transactions for $1.67 million activity. $255,168 worth of EXACT Sciences Corporation (NASDAQ:EXAS) was sold by Conroy Kevin T on Monday, March 13. Another trade for 8,668 shares valued at $186,429 was made by LIDGARD GRAHAM PETER on Friday, February 24. ARORA MANEESH had sold 11,114 shares worth $238,968 on Friday, February 24. 1,543 EXACT Sciences Corporation (NASDAQ:EXAS) shares with value of $36,631 were sold by COWARD D SCOTT.

Wall Street await EXACT Sciences Corporation (NASDAQ:EXAS) to release earnings on July, 25. Analysts forecast EPS of $-0.37, up exactly $0.09 or 19.57 % from 2014’s $-0.46 EPS. After posting $-0.32 EPS for the previous quarter, EXACT Sciences Corporation’s analysts now forecast 15.63 % negative EPS growth. About 861,750 shares traded. EXACT Sciences Corporation (NASDAQ:EXAS) has risen 458.24% since July 17, 2016 and is uptrending. It has outperformed by 441.54% the S&P500.

EXACT Sciences Corporation (NASDAQ:EXAS) Ratings Coverage

Among 14 analysts covering EXACT Sciences (NASDAQ:EXAS), 8 have Buy rating, 1 Sell and 5 Hold. Therefore 57% are positive. EXACT Sciences had 39 analyst reports since July 24, 2015 according to SRatingsIntel. Canaccord Genuity maintained the shares of EXAS in report on Wednesday, October 7 with “Buy” rating. As per Thursday, October 1, the company rating was initiated by Craig Hallum. As per Wednesday, May 31, the company rating was maintained by Roth Capital. The firm has “Buy” rating by Canaccord Genuity given on Monday, August 24. On Wednesday, May 4 the stock rating was downgraded by Mizuho to “Neutral”. Canaccord Genuity maintained it with “Buy” rating and $3800 target in Wednesday, June 7 report. The stock of EXACT Sciences Corporation (NASDAQ:EXAS) earned “Buy” rating by Jefferies on Tuesday, July 4. TH Capital maintained EXACT Sciences Corporation (NASDAQ:EXAS) on Tuesday, October 6 with “Buy” rating. The firm earned “Hold” rating on Tuesday, October 6 by Benchmark. The stock of EXACT Sciences Corporation (NASDAQ:EXAS) earned “Buy” rating by Roth Capital on Tuesday, October 6.

Exact Sciences Corporation is a molecular diagnostics company. The company has market cap of $4.57 billion. The Firm focuses on the early detection and prevention of some forms of cancer. It currently has negative earnings. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer.

More important recent EXACT Sciences Corporation (NASDAQ:EXAS) news were published by: Nasdaq.com which released: “Why Exact Sciences (EXAS) Could Beat Earnings Estimates Again” on June 28, 2017, also Fool.com published article titled: “Why Exact Sciences Corp. Fell 7.5% In June”, Prnewswire.com published: “Exact Sciences to host second-quarter 2017 results, annual meeting webcasts …” on July 10, 2017. More interesting news about EXACT Sciences Corporation (NASDAQ:EXAS) was released by: Prnewswire.com and their article: “Jerry Kelly and Exact Sciences Team Up to Promote Colon Cancer Screening” with publication date: June 22, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: